Healthcare has long been seen as a defensive safe haven but that narrative is starting to shift. A new generation of ETFs is focusing on innovation, biotech breakthroughs, and specialized segments rather than traditional pharma giants. These funds reflect how capital is moving within the sector, from stability toward growth and disruption. The result is a completely different risk-reward profile. The key question is whether this transformation is just beginning or already priced in.

The healthcare sector is acting as a classic defensive shelter this year at a time when investors are becoming more wary of highly priced AI titles. After years of below-average performance, there is renewed enthusiasm. A wave of mergers and acquisitions, a return of interest in healthcare giants and a parallel explosion of thematic funds on narrowly defined trends such as weight-loss drugs are to blame. But this sector is specific in its own way and behaves differently from the rest of the market. Choosing…